Selective Depletion of Mutant p53 by Cancer Chemopreventive Isothiocyanates and Their Structure-Activity Relationships

被引:74
作者
Wang, Xiantao [1 ]
Di Pasqua, Anthony J. [1 ]
Govind, Sudha [1 ]
McCracken, Erin [1 ]
Hong, Charles [1 ]
Mi, Lixin [1 ]
Mao, Yuehua [2 ]
Wu, Jessie Yu-Chieh [1 ]
Tomita, York [1 ]
Woodrick, Jordan C. [1 ]
Fine, Robert L. [2 ]
Chung, Fung-Lung [1 ]
机构
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA
[2] Columbia Univ, Coll Phys & Surg, Div Med Oncol, New York, NY 10032 USA
关键词
PHENETHYL ISOTHIOCYANATE; INDUCED APOPTOSIS; CELL-LINES; GAIN; INDUCTION; MECHANISM; MUTATION; BINDING;
D O I
10.1021/jm101199t
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Isothiocyanates (ITCs) derived from cruciferous vegetables induce apoptosis in cancer cells. We demonstrate that certain naturally occurring ITCs selectively deplete mutant p53 but not the wild-type and do so via a transcription-independent mechanism. Direct p53 binding followed by conformational changes appears to be a mechanism by which mutant p53 is depleted. Structure-activity relationship studies (SARs) using naturally occurring and synthetic ITCs show that depletion is influenced by the ITC side-chain moiety. Furthermore, we show that cells with p53 mutations are more sensitive to cytotoxicity induced by phenethyl isothiocyanate (PEITC) than those with the wild-type protein. 2,2-Diphenylethyl ITC, a synthetic ITC, is one of the most potent depletors of mutant p53 studies and induces apoptosis to the greatest extent in mutant p53 breast cancer cells. Collectively, this study shows that mutant p53 depletion may be an important novel target for cancer chemoprevention and therapy by natural and synthetic ITCs.
引用
收藏
页码:809 / 816
页数:8
相关论文
共 20 条
[1]   Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression [J].
Bossi, G ;
Lapi, E ;
Strano, S ;
Rinaldo, C ;
Blandino, G ;
Sacchi, A .
ONCOGENE, 2006, 25 (02) :304-309
[2]  
De Flora S, 2003, CANCER RES, V63, P793
[3]   Multiple primary cancers in families with Li-Fraumeni syndrome [J].
Hisada, M ;
Garber, JE ;
Fung, CY ;
Fraumeni, JF ;
Li, FP .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (08) :606-611
[4]   p53: 25 years after its discovery [J].
Hofseth, LJ ;
Hussain, SP ;
Harris, CC .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (04) :177-181
[5]  
Huang CS, 1998, CANCER RES, V58, P4102
[6]  
Hussain SP, 1998, CANCER RES, V58, P4023
[7]  
JIAO D, 1994, CANCER RES, V54, P4327
[8]   Monochlorobimane fluorometric method to measure tissue glutathione [J].
Kamencic, H ;
Lyon, A ;
Paterson, PG ;
Juurlink, BHJ .
ANALYTICAL BIOCHEMISTRY, 2000, 286 (01) :35-37
[9]   Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome [J].
Lang, GA ;
Iwakuma, T ;
Suh, YA ;
Liu, G ;
Rao, VA ;
Parant, JM ;
Valentin-Vega, YA ;
Terzian, T ;
Caldwell, LC ;
Strong, LC ;
El-Naggar, AK ;
Lozano, G .
CELL, 2004, 119 (06) :861-872
[10]  
Li Y, 2003, CANCER RES, V63, P1527